RxDoctor Payments Data

Deepak Shah, MD

Cardiovascular Disease · Jersey City, NJNPI 1831258607

Payments from drug & device makers

$1,772in general payments, 2019–2025

Across 42 payments — averaging $42.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$366
  • Abbott$282
  • Bard Peripheral Vascular, Inc.$219
  • Merck$216
  • Novartis$210
  • Biotronik Inc.$139
  • plus $341 from 7 others

What the payments were for

  • Food & beverage$1,75099%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,772 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$114,013
Medicare patients
383
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$76,588
EntrestoSacubitril/Valsartan45$47,994
FarxigaDapagliflozin Propanediol21$31,067
JardianceEmpagliflozin12$15,096
Janumet XrSitagliptin Phos/Metformin Hcl19$13,007
XareltoRivaroxaban12$7,919
Atorvastatin Calcium261$3,058
Metoprolol Succinate167$2,220
Amlodipine Besylate225$1,643
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid11$1,450
Rosuvastatin Calcium60$1,215
Losartan Potassium117$1,005
Ezetimibe25$944
Levothyroxine Sodium66$719
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide60$679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$76,58873 claims
NovartisEntresto$210$47,99445 claims
MerckJanumet Xr$216$13,00719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →